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Abstract. 
Objective: To evaluate the prognostic value of high-sensitivity troponin (hsT) in severe 
aneurysmal subarachnoid hemorrhage (aSAH). 
Methods: This prospective non-interventional study was performed at a surgical intensive 
care unit (ICU) from 2012 to 2015. Consecutive patients who had severe aSAH were 
included. A modified Rankin Scale score ≥ 4 or death within 3 months defined a poor 
outcome. hsT levels were measured at ICU admission and 72 hours following symptom onset. 
Results: A total of 137 patients were analyzed. The median hsT level was 29 ng/L (range: 7-
4485). The best threshold level of hsT for predicting a poor outcome was 22 ng/L. At this 
threshold, the sensitivity was 71% (95% confidence interval [CI]: 58%-81%) and the 
specificity was 58% (95%CI: 46%-70%). The area under the ROC curve was 0.61 (95%CI: 
0.52-0.71). Based on a multivariate analysis, the independent factors for a poor neurological 
prognosis were a World Federation of Neurologic Surgeons (WFNS) score ≥ 4 (odds ratio 
[OR]: 2.61; 95%CI: 1.04-6.56) and an hsT level > 22 ng/L (OR: 2.80; 95%CI: 1.18-6.64). 
Conclusion: In patients with severe aSAH, with regard for the severity of disease (assessed 
by the WFNS score), an hsT level > 22 ng/L at ICU admission was associated with poor 
outcomes. 
 
Key words: Aneurysmal subarachnoid hemorrhage, critical care, high-sensitivity troponin, 
outcome. 
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Introduction. 
In the acute phase of aneurysmal subarachnoid hemorrhage (aSAH), cardiac involvement is 
frequent, but its manifestations vary from a simple electrocardiographic abnormality(ies) with 
no clinical consequence to cardiogenic shock with pulmonary edema [1]. The underlying 
mechanism is related to a sympathetic hyperactivation with a sudden increase in plasma 
catecholamines, notably norepinephrine, and in the most severe form, involves myocardial 
stunning with severe left ventricular dysfunction secondary to focal myocardial necrosis and 
an increase in cardiac enzymes [2]. 
 
The consequences of myocardial damage on the prognosis of aSAH warrant early detection 
by assessing cardiac enzymes and performing electrocardiogram(s) and/or 
echocardiography(s) and for patients presenting overt myocardial dysfunction or 
hemodynamic instability, by echocardiography and/or pulmonary artery catheterization [3-5]. 
In this context, the troponin assay is a biological reference test [1]. Elevation in cardiac 
troponin I or troponin T has been found to be associated with an increased risk of 
cardiopulmonary morbidity, delayed cerebral ischemia, and adverse functional outcome, 
although conflicting results have been reported [6-12]. Hence, due to their increased 
sensitivity and potential for enabling early diagnosis, high-sensitivity troponin T (hsT) assays, 
which are characterized by a coefficient of variation ≤ 10% at the 99th centile of a healthy 
reference population, have been developed and incorporated with other molecular assays for 
acute coronary disease [13]. In patients suffering from aSAH, hsT assays have a high 
sensitivity and specificity for detecting stress-induced cardiomyopathy; additionally, in one 
study, high levels of hsT detected shortly after symptom onset was independently associated 
with an adverse neurologic prognosis at one year [14,15]. Nevertheless, the intrinsic severity 
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of the disease may be relevant for limiting the accuracy of troponin (“standard” or “high 
sensitivity”) to predict outcomes independent of the occurrence of myocardial damage. 
In this context, the aim of this prospective study was to evaluate the accuracy of hsT in 
predicting functional outcomes and mortality in patients with severe aSAH under intensive 
care. 
 
Methods. 
Study design and setting 
This prospective non-randomized observational study was conducted between October 2012 
and August 2015 at the surgical intensive care unit (ICU) of a university hospital. The study 
was approved by the Institutional Review Board of University Hospital and written consent 
was not required according to the observational design of the study. 
Patients 
Severe aSAH was defined as aSAH requiring an ICU stay. All patients over 18 years of age 
who were admitted for aSAH at the surgical department were consecutively included. Patients 
with non-aSAH (due to arteriovenous malformation, head trauma or unknown etiology) or 
patients admitted to the ICU more than 48 hours after the onset of initial symptoms were 
excluded. Patients were followed up for a period of three months after inclusion.  
 
Objectives 
The main objective of the study was to evaluate the predictive value of hsT regarding 
neurological outcomes assessed by the modified Rankin Scale (MRS) at 3 months, with a 
poor prognosis being defined by an MRS score ≥ 4 or death [16]. The MRS score ranges from 
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0 to 6 (0 = no symptom, 1 = no significant disability despite symptoms, 2 = slight disability, 
unable to perform all activities but does not need assistance, 3 = moderate disability, 4 = 
moderately severe disability, unable to walk without assistance, 5 = severe disability, 
bedridden, incontinent and requires constant nursing care, and 6 = death) and is classified by 
rehabilitation physicians. The secondary objectives were to determine the impact of 
hemodynamic data (heart rate and mean arterial pressure [MAP] at admission and the use of 
catecholamines during the first 24 hours of ICU hospitalization), electrocardiogram 
abnormalities, cardiac dysfunction, and delayed cerebral ischemia on outcomes.  
 
Diagnostic criteria and assessment of severity of aSAH 
The diagnosis of SAH was made by cerebral computed tomography (CT), and the presence of 
an aneurysm was identified by cerebral computed angiography and/or cerebral angiography. 
Disease severity was assessed according to the World Federation of Neurologic Surgeons 
(WFNS) classification and the modified Fisher scale [17,18]. 
 
Data collection 
The following data were collected: age, sex, body mass index (BMI), history of smoking, 
arterial hypertension, heart failure and/or ischemic heart disease, interval between symptom 
onset and ICU admission, disease severity assessed by the WFNS and Fisher scores, location 
of the aneurysm, presence or absence of initial hydrocephalus, and method of aneurysm 
control (coil vs clip). Creatinine levels and creatinine clearance (based on the Modification of 
the Diet in Renal Disease (MDRD) study equation) were reported. 
A delayed cerebral ischemia was considered in the case of a new focal neurological deficit or 
deterioration in consciousness or in the Glasgow coma scale and the appearance of new 
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infarctions on cerebral CT or magnetic resonance imaging (MRI) in the absence of other 
explanations (e.g., neurosurgical or radiological intervention, perihematomal edema) during 
hospitalization and by MRI at 3 months in surviving patients [19]. In our institution, at 3 
months, patients are systematically evaluated by MRI and evaluated for neurologic 
performance by a physician. 
 
Heart rate and mean arterial pressure (MAP) at admission and the use and nature of 
catecholamines administered during the first 24 hours of ICU admission were recorded. A 12-
lead electrocardiogram was performed at admission, and the following modifications were 
evaluated and notified: ST segment elevation or depression, negative T wave, atrial 
fibrillation, and/or left branch block (BBG). Additionally, echocardiography was performed 
during the first 24 hours of ICU admission, and left systolic ventricular function was 
calculated. Left ventricular dysfunction was defined as a left ventricular ejection fraction 
(LVEF) < 50%. 
 
High-sensitivity troponin assay 
Blood hsT levels were determined within 24 hours of admission (within 72 hours of symptom 
onset). Troponin levels and intervals between symptom onset and ICU admission were also 
recorded. Serum hsT was measured with an Elecsys Troponin T High-Sensitivity 
Immunoassay (Elecsys ® Troponin T – high-sensitive - Roche Diagnostics, Rotkreuz – 
Switzerland). The values were expressed in ng/L, and the lowest concentration with a 
coefficient of variation ≤ 10% (limit of quantification) was 13 ng/L. 
 
Statistical analysis 
SAS software version 9.4 (SAS Institute, Cary, NC) and R software V 3.3.1 (package pROC) 
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were used to perform statistical analyses. Quantitative and qualitative variables were 
expressed as the median (interquartile range) and numbers (percentage), respectively. The 
first step was to select the optimal level of hsT that differentiated patients with good and poor 
outcomes at 3 months based on receiver operating characteristic (ROC) curves and the 
Youden index. Therefore, from the defined threshold level of hsT, the risk factors of poor 
outcome were determined by logistic regressions and expressed by odds ratios (ORs) and 95% 
confidence intervals (CIs). Variables > 0.20 in univariate analysis were included in the 
multivariate model. For analyses, a p < 0.05 (two-sided) was considered significant. 
 
The primary outcome was the calculated sensitivity and specificity with corresponding 95% 
CIs. We specified a priori estimates of approximately 50% as no, approximately 75% as 
moderate and approximately 100% as excellent clinical test performance to interpret 
sensitivity and specificity (considered robust estimates) rather than positive or negative 
predictive values (which can be altered by disease prevalence). We estimated that a sample 
size of 140 patients would yield 80% power to detect 95% CIs no wider than 20% around 
sensitivity and specificity estimates provided these operating characteristics were 
approximately 75% using sample size calculations detailed by Flahault et al. [20]. 
 
Results. 
A total of 160 patients were admitted for SAH to the surgical ICU during the study period, 
and 137 patients were finally included (Figure 1). The characteristics of the population are 
presented in Table 1. Sixty-five patients (47%) had a poor neurologic outcome at 3 months 
(MRS score ≥ 4). Twenty-two (16%) patients had MRS scores 4 to 5, and 43 (31%) patients 
died (40 in the ICU and 3 after discharge from the ICU). Of the 25 patients (18%) who died 
within 72 hours of ICU admission, 22 (88%) did not have their aneurysms secured because of 
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initial poor prognosis. The delays from hsT measurement and symptom onset to ICU 
admission are presented in Figure 2.  
Prognostic value of high-sensitivity troponin 
The median hsT level at admission was 29 ng/L (interquartile range 25-75: 10-212 ng/L). The 
best threshold level of hsT for predicting a poor outcome was 22 ng/L. At this threshold, the 
sensitivity was 71% (95% CI: 58%-81%), the specificity was 58% (95% CI: 46%-70%) and 
the positive and negative predictive values were 60% (95% CI: 49%-72%) and 69% (95% CI: 
56%-80%), respectively. The area under the ROC curve was 0.61 (95% CI: 0.52-0.71) (Figure 
3). 
The results of the univariate analysis are provided in Table 1. The hsT level was significantly 
different between patients with favorable or unfavorable outcomes (Table 1). The multivariate 
analysis included the following variables: age, WFNS score, modified Fisher scale, aneurysm 
control (reference = no treatment vs clip or coil), creatinine clearance (MDRD) and hsT level 
(> 22 vs ≤ 22 ng/L). An hsT level > 22 ng/L measured early after admission and a WFNS 
score ≥ 4 were independent predictors of poor neurological prognoses. Securing of the 
aneurysm was a protective factor regardless of the method (clipping or coiling) (Table 2). The 
distribution of MRS scores according to the threshold of hsT > 22 vs ≤ 22 ng/L is shown in 
Figure 4. 
Secondary criteria 
Hemodynamic data, electrocardiogram findings, and echocardiographic LVEF are presented 
in Table 3. There was no significant difference in outcomes at 3 months regardless of the 
parameters studied. 
Delayed cerebral ischemia was evaluated in 132 patients. At 3 months, among the 94 
surviving patients, MRI was available in 89 (there was loss of follow up in 5 patients [MRS 
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score < 4, n = 4 and MRS score ≥ 4, n = 1]), and there was no significant difference between 
the two groups in the occurrence of delayed cerebral ischemia (MRS score ≥ 4, n = 29/64 
(45%) vs MRS score < 4, n = 30/68 (44%), p = 0.890). 
Discussion 
 
In patients with severe aSAH requiring ICU admission at the acute phase, we found an 
association between admission hsT values > 22 ng/L and the prognosis at 3 months as 
assessed by the MRS score. This threshold was chosen based on the guidance of the Youden 
index to maximize misclassification by the ROC curve. Although the hsT level alone helped 
with achieving a prognosis for the 3-month outcome with a moderate sensitivity and 
specificity, these results may be better interpreted in a larger multivariate study including 
clinical variables. Severity assessed as an WFNS score ≥ 4 was also an independent risk 
factor of a poor outcome at 3 months. 
Several groups have studied the relationship between troponin levels and cardiac 
complications, but few have examined long-term prognosis. Naidech et al. found that the peak 
level of troponin I was associated with death or severe disability at discharge but not at 3 
months. In this prospective study including 253 patients, troponin level was measured only in 
patients who had abnormal electrocardiograms or symptoms of cardiac dysfunction, allowing 
for the selection of a certain population with SAH [7]. In a retrospective study, troponin levels 
were measured in 203/225 patients who had a non-traumatic SAH. A troponin level > 0.5 
µg/L was not associated with in-hospital mortality in multivariate analysis, but age and 
severity assessed by the Hunt and Hess score were [11]. In 301 patients with aSAH, 
abnormalities in cardiac wall motion evaluated by echocardiography, but not troponin T, was 
found to be an independent factor of mortality and poor outcome (MRS score ≥ 4) [5]. In 163 
patients who had non-traumatic aSAH, elevation in troponin T levels was found to be 
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associated with a 30-day mortality, but this association did not reach statistical significance 
when controlling for the WFNS score or Glasgow coma scale, suggesting that the intrinsic 
severity of aSAH was more relevant than the troponin level in outcome prediction [12]. In 
contrast, in 68 patients who had aSAH, Schuiling et al. found that troponin I level ≥ 0.3 µg/L 
was an independent risk factor for poor outcomes at 3 months, although the addition of 
troponin to variables related to the severity of the aSAH only slightly improved the prognostic 
value [21]. More recently, poor outcomes evaluated by the Glasgow Outcome Scale score (1 
to 3) and MRS score (4 to 6) at 3 months have been shown to be independently associated 
with troponin levels ≥ 0.3 µg/L [10]. The prospective study was conducted in 239 patients 
with aSAH, and only 84% of patients were effectively evaluated at 3 months. Finally, in a 
cohort of 368 patients, Degos et al. found that a Glasgow coma scale at admission < 13 and 
high levels of troponin and S100β (> 0.5 µg/L) were independently associated with mortality 
at 1 year, but only patients treated by coils were included in that study, excluding those 
treated by clip and those who were received neither clips nor coils [22]. 
In this context, hsT may provide good prognostic accuracy. Moreover, to the best of our 
knowledge, only one other study has evaluated the accuracy of hsT in predicting outcome. In 
a prospective study performed using the same kit to obtain hsT measurement that was used in 
our study, Oras et al. showed that in addition to age, the presence of cerebral infarction and 
WFNS scores 4-5, the peak hsT level (per 100 ng/L) was associated with poor neurological 
outcomes (Glasgow Outcome Scale score ≥ 4) at one year. The best threshold of hsT to 
predict poor outcome was 51 ng/L, with a specificity of 84%, a relatively low sensitivity 
(56%) and an area under the curve of 0.74 [14]. The study also showed higher heart rate and 
norepinephrine doses in patients with poor neurologic prognoses, suggesting that 
hemodynamic instability and an increase in cerebral metabolic demand may have favored 
brain ischemia. Our results are in accordance with these results, as we found an association 
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between hsT levels > 22 ng/L and outcome. Nevertheless, there was no difference in 
hemodynamic parameters, electrocardiograms or cardiac dysfunction assessed by 
echocardiography between patients with good and poor outcomes. Obviously, a small increase 
in the hsT level (the threshold of detection was 13 ng/L) can impact the prognosis. 
Nevertheless, it must be emphasized that while a threshold of 22 ng/L is potentially useful for 
physicians to identify patients at higher risk of poor outcomes, these data must be interpreted 
with caution. Indeed, the positive predictive value was relatively low (60%), and some 
patients achieved a good outcome despite having a high hsT level. The originality of our 
study is its focus on a selective population, as we recruited patients with more severe aSAH. 
In our study, more than 90% of patients had a Fisher score = 4 (compared to 31% in the Oras 
et al. study). Accordingly, contrary to the Oras et al. study, the mortality was higher (30% vs 
14%), and patients who did not have their aneurysms secured were also included [14]. 
Nevertheless, our study has some limitations that must be noted. Some may argue that we 
have measured the level of troponin only at admission and early in the course of the disease. 
Nevertheless, it has been shown that troponin levels peak early in the course of disease, 
usually during the first hours of hospitalization (10,12) and decreases thereafter; therefore, we 
believe that based on a practical point of view and real-life situations, the level of troponin at 
admission is sufficient to categorize patients at risk of poor outcome. From this practical point 
of view, there is variability among troponin levels and symptom onset and the time of 
admission into the ICU, and we cannot rule out that a higher level of troponin may have been 
present. Moreover, we have not included a validation cohort to verify our cut off level of 
troponin in terms of risk prediction in our analysis. An external assessment and validation of 
the performance of biological-clinical scores would therefore be meaningful. In fact, it was 
difficult to perform such an analysis as it was necessary to prolong the study to nearly 3 years 
to include 137 patients. Furthermore, the threshold of 22 ng/L must be interpreted with regard 
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for its moderate sensitivity and specificity and the finding that it did not preclude a good 
outcome. Such a threshold must alert physicians about the higher risk of a poor outcome but 
should not be used to make decisions regarding the intensity of care. Finally, we analyzed the 
prognosis at 3 months and not at one year, as did Oras et al. [14]. Even if major neurological 
complications arise within 3 months, we cannot completely rule out that patients will 
functionally recover beyond this time, although most studies have evaluated the prognostic 
value of troponin at 3 months [7,10,21,22]. 
In conclusion, following the severity of aSAH, the plasma level of hsT at admission is 
significantly associated with the neurological outcome at three months in patients with aSAH 
admitted to the ICU. 
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Figure legends. 
Figure 1: Flow chart. 
Figure 2: Delay between hsT measurement and symptom onset (A) and ICU admission (B). 
Figure 3: Receiver operating characteristic curve. 
Figure 4: Distribution of modified Rankin Scale scores according to the level of hsT: > or ≤ 
22 ng/L.  mRS: modified Rankin scale (see text for definition). 
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Fig. 2 
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Fig. 3 
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Fig. 4 
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Table 1: Patients characteristics. 
 Total 
(n=137) 
MRS* 
0 to 3 
(n=72) 
MRS* 
4 to 6 
(n=65) 
p 
Age, years 54 (46-63) 54 (46-60) 58 (46-65) 0.055 
Sex, female 95 (69 %) 48 (67%) 47 (72%) 0.475 
Body mass index, kg/m² 24 (21-28) 24 (21-28) 24 (20-28) 0.766 
Medical history      
    Smoking 59 (43%) 33 (46%) 26 (40%) 0.491 
    Arterial hypertension 39 (28%) 23 (32%) 16 (25%) 0.342 
    Coronary artery disease  2 (1%) 2 (3%) 0 0.498 
    Congestive heart failure 0 0 0 - 
Delay between ICU admission 
and onset of symptoms, hours 
7 (4-14) 7 (5-15) 6 (4-10) 0.332 
WFNS
§
 classification <0.001 
   WFNS 1 15 (11%) 15 (21%) 0  
   WFNS 2 21 (15%) 14 (19%) 7 (11%)  
   WFNS 3 9 (7%) 5 (7%) 4 (6%)  
   WFNS 4  36 (26%) 21 (29%) 15 (23%)  
   WFNS 5 56 (41%) 17 (24%) 39 (60%)  
Modified Fisher scale 0.011 
    Fisher 1 0 0 0  
    Fisher 2 3 (2%) 3 (4%) 0  
    Fisher 3 9 (7%) 8 (11%) 1 (1%)  
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    Fisher 4 125 (91%) 61 (85%) 64 (98%)  
Aneurysm location     0.342 
    Anterior communicating  artery 54 (41%) 29 (41%) 25 (40%)  
    Middle cerebral artery 43 (33%) 19 (27%) 24 (39%)  
    Internal carotid artery  20 (15%) 11 (16%) 9 (14%)  
    PICA
§§
 4 (3 %) 4 (6%) 0  
    Posterior communicating  artery 2 (1%) 1 (1%) 1 (2%)  
    Others 9 (7%) 6 (9%) 3 (5%)  
Hydrocephalus 67 (49%) 32 (44%) 35 (54%) 0.272 
Aneurysm treatment (ref= no treatment) <0.001 
None 22 (16%) 2    (3%) 20 (31%)  
Clipping 29 (21%) 11 (15%) 18 (28%)  
Coiling 86 (63%) 59 (82%) 27 (41%)  
hsT, ng/L 29 (10-
212) 
19 (7-187) 57 (17-
255) 
0.024 
Delay between troponin measurement 
and onset of symptoms, hours 
10 (6-22) 11 (6-23) 10 (5-21) 0.609 
Delay between troponin measurement 
and ICU admission, hours 
1 (1-5) 1 (1-4) 1 (1-6) 0.399 
Creatinine, µmol/L 56 (46-67) 57 (46-68) 56 (46-66) 0.789 
Clearance creatinine MDRD, ml/min
‡
 113 (94-
138) 
116 (95-
144) 
110 (93-
137) 
0.159 
Values are expressed as median (interquartile range 25-75) or n (percentage).
 
*MRS: 
Modified Rankin scale. 
§
WFNS: World Federation of Neurosurgical Societies.
 §§
PICA: 
Postero inferior cerebellar artery. 
‡
MDRD:
 
Modification of the Diet in Renal Disease. 
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Table 2: Independent risk factors of poor outcome at 3 months. 
 OR [CI 95%] p 
Aneurysm treatment (ref=no treatment) <0.001 
-Clipping 0.21 [0.04 ; 1.15]  
-Coiling 0.05 [0.01 ; 0.25]  
WFNS* 4 and 5 
hsT
§
 > 22ng/L 
2.61 [1.04 ; 6.56] 
2.80 [1.18 ; 6.64] 
0.042 
0.020 
*WFNS: World Federation of Neurosurgeries society. 
§
high-sensitivity troponin 
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Table 3: Hemodynamic, electrocardiogram and echocardiographic data. 
  Total 
(n=134) 
MRS* 
0 to 3 
 (n=71) 
MRS* 
4 to 6 
(n=63) 
p 
Heart rate, rate/min 74 (63-88) 74 (62-85) 74 (65-95) 0.280 
Mean arterial pressure, mmHg 90 (80-101) 90 (80-100) 91 (80-101) 0.483 
Catecholamines use 53 (40%) 24 (34%) 29 (46%) 0.340 
    Norepinephrine 46 (34%) 22 (31%) 24 (38%)  
    Dobutamine 6 (4%) 2 (3%) 4 (6%)  
    Epinephrine 1 (1%) 0 1 (2%)  
Electrocardiogram (n=131)     
      ST segment elevation or  
depression 
14 (11%) 7 (10%) 7 (11%) 0.785 
      Negative T wave 23 (18%) 11 (16%) 12 (20%) 0.553 
      Atrial fibrillation 5 (4%) 2 (3%) 3 (5%) 0.663 
      Left block branch 6 (5%) 3 (4%) 3 (5%) 1.000 
Echocardiography (n=98)     
      LVEF
§
< 50% 16 (16%) 6 (11%) 10 (22%) 0.160 
Values are expressed as median (interquartile range 25-75) or n (percentage). *MRS: 
modified Rankin Scale. 
§
LVEF: Left ventricular ejection fraction. 
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